LPC
ACRS icon

Lion Point Capital’s Aclaris Therapeutics ACRS Stock Holding History

Lion Point Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-115,898
Closed -$122K – 33
2023
Q4 		$122K Hold
115,898
– – 0.06% 27
2023
Q3 		$794K Buy
115,898
+6,000
+5% +$51.3K 0.35% 19
2023
Q2 		$1.14M Hold
109,898
– – 0.52% 14
2023
Q1 		$889K Buy
+109,898
New +$1.39M 0.37% 20

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lion Point Capital's ACRS Position: Q1 2024 in Review

Lion Point Capital sold out of Aclaris Therapeutics (ACRS) in Q1 2024, closing a stake of 115,898 shares — an estimated $122K sold.

Lion Point Capital first reported a position in ACRS in Q1 2023 and held it in 4 quarters. The position peaked at $1.14M in Q2 2023. 98 funds tracked by Wall St. Rank hold ACRS as of Q1 2024.

  • Lion Point Capital reported no remaining Aclaris Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Lion Point Capital sold 115,898 Aclaris Therapeutics shares in Q1 2024, an estimated $122K.
  • Lion Point Capital first reported a position in Aclaris Therapeutics in Q1 2023 and held it in 4 quarters.
  • Lion Point Capital's Aclaris Therapeutics position peaked at $1.14M in Q2 2023.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2024.

Based on Lion Point Capital's 13F filing for Q1 2024, filed 15 May 2024.